reports
- ABGSC Seafood Research
- Martin Kaland
- Simon Brun
- ABGSC Seafood Research
- Martin Kaland
- Simon Brun
Ultimovacs ASA: Invitation to first quarter 2024 results webcast prese...
Ultimovacs ASA: Invitation to first quarter 2024 results webcast presentation Oslo, April 30, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, invites to a webcast presentation of its first quarter 2024 results on Tuesday, May 7, 2024. The presentation can be followed as a live webcast accessed through a link on at 14:00 CET on Tuesday, May 7, 2024, and is scheduled to conclude at 14:55 CET. The webcast presentation will be available on the Ultimovacs website, and it will be possible to post questions duri...
Lerøy Seafood Group ASA: Key information relating to the cash dividend...
Lerøy Seafood Group ASA: Key information relating to the cash dividend to be paid by Lerøy Seafood Group ASA Dividend amount: NOK 2.5 per shareDeclared currency: NOKLast day including right: 28 May 2024Ex-date: 29 May 2024Record date: 30 May 2024Payment date: 5 June 2024Date of approval: 28 May 2024 This information is published in accordance with the requirements of the Oslo Børs Rule Book II section 4.2.4 (1) no. 3.
Lerøy Seafood Group ASA: Annual report for 2023
Lerøy Seafood Group ASA: Annual report for 2023 Please find attached Lerøy Seafood Group ASA's annual report for 2023. The annual report is also attached in a machine-readable format according to ESEF (European Single Electronic Format). As part of the group’s integrated reporting, an overview of priorities, measurements, and targets within environment, social and governance (“ESG”) is included. The Board of Directors has proposed a dividend payment of NOK 2.50 per share for distribution in 2024. Key dates are set out in a separate stock exchange announcement. ...
Lerøy Seafood Group ASA: Årsrapport for 2023
Lerøy Seafood Group ASA: Årsrapport for 2023 Vedlagt følger årsrapport for Lerøy Seafood Group ASA for 2023. Som del av konsernets integrerte rapportering inneholder årsrapporten en oversikt over fokusområder, måleindikatorer og mål innen miljø, samfunnsmessig og finansiell bærekraft (ESG). Årsrapporten er også vedlagt i et maskinlesbart format i tråd med ESEF (European Single Electronic Format). Styret har foreslått et utbytte til utbetaling i 2024 på NOK 2,50 per aksje. Det vises til egen børsmelding med relevante datoer. ...
- Alexander Aukner
LSG LEROY SEAFOOD GROUP ASA
AUSS AUSTEVOLL SEAFOOD ASA
AKVA AKVA GROUP ASA
SALM SALMAR ASA
GSF GRIEG SEAFOOD ASA
MOWI MOWI ASA
BAKKA BAKKAFROST P/F
SALMOCAM SALMONES CAMANCHACA SA
IFISH ICE FISH FARM AS
ASA ATLANTIC SAPPHIRE
SALME SALMON EVOLUTION HOLDING
KING THE KINGFISH COMPANY NV
AKBM AKER BIOMARINE
ISLAX ARNARLAX AS
AFISH ARCTIC FISH HOLDING AS
MAS MÅSØVAL
Ultimovacs Announces Poster Presentation at the 2024 American Society ...
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting NON-REGULATORY PRESS RELEASE Oslo, April 24, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that the data from the Phase II clinical trial INITIUM (), will be presented in a poster session at the 2024 ASCO Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, IL & Online. INITIUM is an Ultimovacs-sponsored randomized, comparative, multi...
- Alexander Aukner
LSG LEROY SEAFOOD GROUP ASA
AUSS AUSTEVOLL SEAFOOD ASA
AKVA AKVA GROUP ASA
SALM SALMAR ASA
GSF GRIEG SEAFOOD ASA
MOWI MOWI ASA
BAKKA BAKKAFROST P/F
SALMOCAM SALMONES CAMANCHACA SA
IFISH ICE FISH FARM AS
ASA ATLANTIC SAPPHIRE
SALME SALMON EVOLUTION HOLDING
KING THE KINGFISH COMPANY NV
AKBM AKER BIOMARINE
ISLAX ARNARLAX AS
AFISH ARCTIC FISH HOLDING AS
MAS MÅSØVAL
Ultimovacs ASA – Annual General Meeting held on April 18, 2024
Ultimovacs ASA – Annual General Meeting held on April 18, 2024 Oslo, April 18, 2023: Ultimovacs ASA held its annual general meeting today April 18, 2024. All the matters on the agenda were approved. The following board members were re-elected for a period of one year, and the Board of Directors will consist of the following persons: Jónas Einarsson, Chair of the BoardHenrik Schüssler, board member Kari Grønås, board member Ketil Fjerdingen, deputy board member The Nomination Committee will consist of the following persons until the Annual General Meeting in 2025: Ole Kristian Hjelstue...
- Sean Conroy
Ultimovacs - Steadfast commitment to UV1 progression
Despite the recent setback with the INITIUM trial (first-line treatment of patients with unresectable or metastatic malignant melanoma), Ultimovacs has reinstated its commitment to press on with its clinical development of its cancer vaccine, UV1, across other target indications. The principal near-term focus will be on the anticipated results of Phase II FOCUS (head and neck cancer) and DOVACC (ovarian cancer) trials in Q324 and H125, respectively, and will inform its subsequent strategic direc...
Ultimovacs Implements Operational Adjustments to Support Continuous Ad...
Ultimovacs Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program Due to the broad diversity in the UV1 Phase II program and the encouraging results from previous UV1 trials, Ultimovacs remain confident in UV1’s potential and are strongly committed to bringing the company across the next important data points: The readout from FOCUS in Q3 2024 and DOVACC results in H1 2025Activity level adjustments and operational prioritization are implemented to sustain the financial runway, including a workforce reduction of approximately 40% Th...
Ultimovacs ASA – Disclosure of voting rights of Annual General Meeting
Ultimovacs ASA – Disclosure of voting rights of Annual General Meeting Oslo, April 15, 2024: In connection with the Annual General Meeting of Ultimovacs ASA to be held on April 18, 2024, Jónas Einarsson, Chair of the Board of Directors, has so far received proxy based voting rights without voting instructions for 9,063,854 shares, representing 26.34% of the total voting rights in the company. The proxies are only valid for the Annual General Meeting on April 18, 2024. This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading A...
- Alexander Aukner
LSG LEROY SEAFOOD GROUP ASA
AUSS AUSTEVOLL SEAFOOD ASA
AKVA AKVA GROUP ASA
SALM SALMAR ASA
GSF GRIEG SEAFOOD ASA
MOWI MOWI ASA
BAKKA BAKKAFROST P/F
SALMOCAM SALMONES CAMANCHACA SA
IFISH ICE FISH FARM AS
ASA ATLANTIC SAPPHIRE
SALME SALMON EVOLUTION HOLDING
KING THE KINGFISH COMPANY NV
AKBM AKER BIOMARINE
ISLAX ARNARLAX AS
AFISH ARCTIC FISH HOLDING AS
MAS MÅSØVAL
Ultimovacs – Invitation to Business Update on April 17, 2024
Ultimovacs – Invitation to Business Update on April 17, 2024 NON-REGULATORY PRESS RELEASE Oslo, April 9, 2024: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced that the company will host a webcast on April 17, 2024, at 11:00. Ultimovacs’ management will provide a company update emphasizing recent developments and the future potential within the clinical program. The presentation will be followed by a Q&A session. Date: Wednesday, April 17...
- Alexander Aukner
LSG LEROY SEAFOOD GROUP ASA
AUSS AUSTEVOLL SEAFOOD ASA
AKVA AKVA GROUP ASA
SALM SALMAR ASA
GSF GRIEG SEAFOOD ASA
MOWI MOWI ASA
BAKKA BAKKAFROST P/F
SALMOCAM SALMONES CAMANCHACA SA
IFISH ICE FISH FARM AS
ASA ATLANTIC SAPPHIRE
SALME SALMON EVOLUTION HOLDING
KING THE KINGFISH COMPANY NV
AKBM AKER BIOMARINE
ISLAX ARNARLAX AS
AFISH ARCTIC FISH HOLDING AS
MAS MÅSØVAL
- Alexander Aukner
Lerøy Seafood (Buy, TP: NOK52.00) - Better harvest mix in Q1
Lerøy Seafood’s Q1 trading update revealed harvest volumes in line with our estimates, but with a better mix on higher-than-expected volumes from Lerøy Midt and lower volumes from Lerøy Sjøtroll in Q1, while higher wild-catch volumes also contributed positively. We have raised our 2024e EPS by 1.5%, and we now expect Q1 operating EBIT of NOK880m (previously NOK752m), in line with consensus of NOK881m (full Q1 report due at 06:30 CET on 15 May). We reiterate our BUY and NOK52 target price.
Lerøy Seafood Group ASA: Trading update Q1 2024
Lerøy Seafood Group ASA: Trading update Q1 2024 HARVEST VOLUMES OF SALMON AND TROUT Total harvest volume of salmon and trout for Q1 2024 was 26,400 GWT, excluding volumes from Scottish Seafarms. Harvest volumes per region/company (in 1,000 GWT): Lerøy Aurora: 6.0 Lerøy Midt: 13.7 Lerøy Sjøtroll: 6.7 (of which 3.3 was trout) CATCH VOLUMES OF WILDFISH Total wild catch volumes (Lerøy Havfisk) was 24,100 tonnes for Q1 2024 of which 6,700 tonnes of cod. The complete Q1 2024 report will be released on 15 May 2024 at 06:30 CET. Queries may be addressed to the company’s CFO Sjur S. M...
Lerøy Seafood Group ASA: Oppdatering volum i første kvartal 2024
Lerøy Seafood Group ASA: Oppdatering volum i første kvartal 2024 SLAKTET VOLUM AV LAKS OG ØRRET Slaktet volum av laks og ørret for første kvartal 2024 ble 26.400 GWT. Dette inkluderer ikke volumer fra Scottish Seafarms. Slaktet volum av laks og ørret per region / havbruksselskap (i 1.000 GWT): Lerøy Aurora: 6,0 Lerøy Midt: 13,7 Lerøy Sjøtroll: 6,7 (hvorav 3,3 var ørret) FANGSTVOLUM VILLFISK Fangstvolum av villfisk (Lerøy Havfisk) utgjorde 24.100 tonn i første kvartal 2024, hvorav 6.700 tonn med torsk. Fullstendig rapport for første kvartal 2024 blir offent...
Ultimovacs to Present Poster at the American Association for Cancer Re...
Ultimovacs to Present Poster at the American Association for Cancer Research (AACR) Annual Meeting 2024 Oslo, April 4, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that the data from the TENDU-101 study in patients with relapse after primary radical prostatectomy (NCT04701021) will be presented in a poster at the 2024 American Association for Cancer Research (AACR), taking place April 5-10, 2024, in San Diego, CA. Additionally, a poster with results related to the Phase I ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.